Analysts estimate that treatment for Alzheimer's could generate sales of at least $20 billion, but the development process carries uncertainty and a high price. The Pharmaceutical Research and Manufacturers of America has said more than 80 drugs are in development, but most have not reached late-stage trials. There is concern that drugmakers may reduce investments in Alzheimer's drug research if the next round of late-stage studies is not promising, Bertha Coombs writes.

Full Story:
NBC News

Related Summaries